PE 42

AF

1FM

2832

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a c ection of information unless it displays a valid OMB control number. Application Number 10/034.826 TRANSMITTAL Filing Date December 28, 2001 First Named Inventor **FORM** Garrett Holmes et al. Art Unit 2832 Examiner Name Bernard Rojas (to be used for all correspondence after initial filing) Attorney Docket Number DKT 00054A (BWI-00055) Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer **Extension of Time Request** below): Return Receipt Postcard Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Applicant believes no fee to be due for the attached filing, however, should Reply to Missing Parts/ additional fees be due in order to prevent the abandonment of this Incomplete Application application, please consider this as authorization to charge Deposit Account Reply to Missing Parts No. 501612 (Warn, Hoffmann, Miller & Ozga, P.C.) for any such fees due. A under 37 CFR 1.52 or 1.53 duplicate copy of this document is enclosed for this purpose. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Warp, Hoffmann, Miller & Ozga, P.C. Signature Printed name Philip R. Warn Date Reg. No. February 15, 2007 32775 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class man A an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Philip R. Warn - 32775 February 15, 2007 Typed or printed name

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/034,826

Filing Date:

December 28, 2001

Applicant:

Garrett Holmes et al.

Group Art Unit:

2832

Examiner:

Bernard Rojas

Title:

VARIABLE BLEED SOLENOID

Attorney Docket:

DKT 00054A (BWI-00055)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE TO OFFICE ACTION

Sir:

This is in response to the Examiner's Office Action dated December 15, 2006, to which a timely response is due by February 15, 2006 in order to provoke an Advisory Action. The Applicant respectfully requests reconsideration of the Examiner's rejections and/or objections in view of the remarks set forth below. Please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 6 of this paper.